The latest price target for Zenas BioPharma (NASDAQ:ZBIO) was reported by Citigroup on October 8, 2024. The analyst firm set a price target for $27.00 expecting ZBIO to rise to within 12 months (a possible 112.26% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Zenas BioPharma (NASDAQ:ZBIO) was provided by Citigroup, and Zenas BioPharma initiated their buy rating.

There is no last upgrade for Zenas BioPharma

There is no last downgrade for Zenas BioPharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenas BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenas BioPharma was filed on October 8, 2024 so you should expect the next rating to be made available sometime around October 8, 2025.

While ratings are subjective and will change, the latest Zenas BioPharma (ZBIO) rating was a initiated with a price target of $0.00 to $27.00. The current price Zenas BioPharma (ZBIO) is trading at is $12.72, which is within the analyst’s predicted range.